BB News InternationalBB NEWS INTERNATIONALThe Breaking Bulletin News Agency
Health and Development

Wegovy Demonstrates Pattern of Liver Marker Improvements in Non-Obese Patients with MASH and Scarring

The findings underscore a vital clinical message that progressive liver disease can impact patients of any body type, shifting the conversation toward early therapeutic intervention in populations frequently overlooked by standard diagnostic screening.

A molecular model of semaglutide

Full articles are free to read through December 10, 2026 (IST). Subscriptions remain available.

DENVER, CO — A groundbreaking data presentation at The Liver Meeting 2026 has challenged the traditional clinical association between severe liver disease and body weight. Novo Nordisk announced results from an exploratory post hoc analysis of its phase three ESSENCE trial, demonstrating that once-weekly injections of Wegovy (semaglutide 2.4 mg) were associated with meaningful improvements in liver injury, fibrosis, and overall disease activity in adults living with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced liver scarring who have a body mass index (BMI) below 27 kg/m². The findings underscore a vital clinical message that progressive liver disease can impact patients of any body type, shifting the conversation toward early therapeutic intervention in populations frequently overlooked by standard diagnostic screening.

The specific subgroup analysis tracked 106 non-obese adult participants out of the first 800 randomized patients undergoing the 72-week interim phase of the trial. Clinicians reported a highly consistent pattern across multiple key biomarkers at week 72, with patients receiving semaglutide 2.4 mg demonstrating a significant reduction in core liver enzymes compared to the placebo cohort. Specifically, alanine aminotransferase (ALT) levels dropped to an estimated treatment ratio of 0.61, while aspartate aminotransferase (AST) levels saw a parallel decrease to an estimated treatment ratio of 0.67. Furthermore, non-invasive blood-based fibrosis markers, including the Enhanced Liver Fibrosis (ELF) score and PRO-C3 (a key marker of type III collagen formation), strongly favored the semaglutide arm, providing vital structural data that supplemented the trial's core biopsy-based histologic endpoints.

MASH remains a largely silent, progressive metabolic disease affecting more than 250 million people worldwide, with nearly 90% of cases going entirely undiagnosed until advanced stages manifest into cirrhosis, liver malignancies, or liver transplantation requirements. While more than 80% of individuals diagnosed with MASH live with concurrent obesity, medical experts emphasize that body size alone does not define the disease's pathobiology. Wegovy 2.4 mg is currently authorized under federal accelerated approval pathways to treat adults with MASH presenting with moderate-to-advanced liver scarring (fibrosis stages F2 or F3) but has not been evaluated or approved for individuals who have already progressed to established cirrhosis of the liver.

Because continued clinical approval for this specific metabolic indication remains contingent upon the verification and description of long-term benefits in ongoing confirmatory trials, the medical community continues to heavily monitor safety data. Semaglutide 2.4 mg carries a prominent Boxed Warning detailing the potential risk of developing thyroid tumors, including medullary thyroid carcinoma (MTC), and is strictly contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN 2). The most frequent adverse transformations recorded during large-scale clinical use include gastrointestinal reactions such as nausea, diarrhea, vomiting, and abdominal pain. Make sure to double-check the physical label to confirm this information regarding proper dosages, administration criteria, and safety profiles.

www.bbnewsin.com